POS1080 HYPERLIPIDEMIA IN PSORIATIC DISEASE: HIGHER PREVALENCE IN PSORIATIC ARTHRITIS AND INVERSE ASSOCIATION WITH SYSTEMIC THERAPY
Authors: R. Queiró Silva, E. Pardo Campo, S. Fernández, L. Arboleya Rodríguez, I. Zapico, F. Jirout
Journal: Annals of the Rheumatic Diseases (2021)

Background: Although the evidence that testifies to a higher prevalence of cardiometabolic risk factors in psoriatic disease is robust, there are not too many studies that have analyzed which disease traits are associated with these risk factors both in psoriasis and psoriatic arthritis 1 . Objectives: We aimed to analyze the frequency and disease-associated features of hyperlipidemia in psoriatic disease. Methods: Cross-sectional observational study that included 290 patients with psoriatic arthritis (mean age 54 ± 12 years, 54.8 % male, psoriasis average duration 21 ± 10 years) and 310 with psoriasis alone (mean age 53 ± 11.5 years, 52.9% male, psoriasis average duration 22 ± 11 years). We first analyzed the frequency of this comorbidity and then the factors associated with it using conditional logistic regression. The significant factors in this first model were introduced in a multivariate model using a backward stepwise approach. Results: Main disease features are depicted in Table 1. A total of 124 patients had hyperlipidemia (20.7%). Among arthritis patients, 82/290 (28.3%) had hyperlipidemia, compared with 42/310 (13.5%) of those with psoriasis alone (OR 2.5, 95%CI: 1.7–3.3, p &lt; 0.001). Hyperlipidemia was independently associated with age [OR 1.07, 95%CI: 1.04–1.11, p &lt; 0.001] and systemic therapy [OR 0.4, 95%CI: 0.17–0.89, p = 0.026]. Conclusion: Hyperlipidemia is common in psoriatic disease, but much more among arthritis patients. This comorbid factor seems to go in parallel with increasing age. There is an inverse association between systemic treatment and hyperlipidemia that should be endorsed with well-designed longitudinal studies. References: [1]Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci 2018; 19: 58. Table 1. Disease characteristics of both subpopulations Variable PsA n = 290 Psoriasis n = 310 p-values Age (yr ± SD) 54 ± 12 53 ± 11.5 NS Age at psoriasis onset (yr ± SD) 32 ± 16 31 ± 14.2 NS Age at arthritis onset (yr ±SD) 46 ± 14 NS Duration of psoriasis (yr ± SD) 21 ± 10 22 ± 11 NS Duration of arthritis (yr ± SD) 11 ± 7.2 NS Male gender (n, %) 159 (54.8) 164 (52.9) NS Primary education (n, %) 145 (50) 148 (47.7) NS Secondary education (n, %) 79 (27.2) 87 (28.1) NS University degree (n, %) 66 (22.8) 235 (24.2) NS Plaque psoriasis (n, %) 250 (86.2) 272 (87.7) NS Nail disease (n, %) 122 (42.1) 110 (35.5) NS Psoriasis in ≥ 3 body areas (n, %) 130 (45) 155 (50) &lt;0.05 Family history of psoriasis (n, %) 130 (45) 136 (44) NS Family history of PsA (n, %) 44 (15.2) 15 (4.8) PASI 6.5 ± 4.3 6.8 ± 3.5 Oligoarthritis (n, %) 122 (42.1) Polyarthritis (n, %) 81 (28) Axial disease (n, %) 17 (5.8) Mixed pattern (n, %) 70 (24.1) Dactylitis (n, %) 87 (30) DIP joint disease (n, %) 72 (24.8) Mutilating arthritis (n, %) 5 (1.7) Erosive disease (n, %) 58 (20) HAQ (mean ± SD) 0.74 ± 0.32 *BASDAI (mean ± SD) 3.64 ± 2.12 Pain VAS (mean ± SD) 4.09 ± 2.64 HLA-B*27 (n, %) 52 (17.9) HLA-C*06 (n, %) 112 (38.6) 124 (40) NS NSAID (n, %) 72 (24.8) 47 (15.2) NS Glucocorticoids (n, %) 34 (11.7) 15 (4.8) NS MTX (n, %) 189 (65.2) 128 (41.3) &lt;0.05 Biologics (n, %) 128 (44.1) 132 (42.6) NS SD, standard deviation; PsA, psoriatic arthritis; PASI, psoriasis area and severity index; DIP, distal interphalangeal joint; HAQ, Health Assessment Questionnaire; BASDAI, bath ankylosing spondylitis disease activity index; VAS, visual analog scale; NSAID, non-steroidal anti-inflammatory drugs. MTX, methotrexate. *Only in patients with axial disease Disclosure of Interests: None declared.